

**Amendments to the Specification**

Please replace page 88 of the specification with the rewritten version thereof that appears on the following page.

**Table 1, cont.**

Composition – Prelyophilate	drug (mg/mL) Acid (Molar)	20-30 1.4	drug (mg/mL) Acid (Molar)	20-30 1.4	NA
	Antioxidant (mg/mL) Captisol (mg/mL) Water for Injection... pH	0-10 200-300 qs to 1.0 mL 1.5-2.0	Antioxidant (mg/mL) Filler (mg/mL) Polysorbate-80(mg) Water for Injection pH	0-10 20-30 0-50 qs to 1.0 mL 1.5-2.0	

Acids used: Methane sulfonic acid, Tartaric acid, Citric acid, succinic acid is used in a 1:1.4 molar ratio for in situ salt formation  
 Cosolvents- PEG-300, PEG-400  
 Surfactants: Polysorbate-80, Cremophor EL  
 Captisol®: Sulfobutylether Cyclodextrin  
 Drug: Compound of Example 2

Please replace the paragraph at page 89, lines 7-13 with the following rewritten version thereof:

The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, ~~and any clones, DNA or amino acid sequences which are functionally equivalent are within the scope of the invention.~~ Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description ~~and accompanying drawings.~~ Such modifications are intended to fall within the scope of the appended claims.